Mayo Clinic, United States

Professor Vicente Torres received MD and Doctoral degrees from the University of Barcelona and moved to the Mayo Clinic in 1972 for research training and residencies in Internal Medicine and Nephrology. During his training, he worked on the role of prostaglandins in acute renal failure (Dr. Cameron G. Strong’s laboratory) and on the distribution and modulation of cyclic nucleotide phosphodiesterases in the kidney (Dr. Thomas P. Dousa’s laboratory). He joined the faculty of the Mayo Clinic in 1979 and became Professor of Medicine in 1991. During the last three decades, his research has focused on polycystic kidney disease (PKD) and related diseases. Professor Torres was PI for the NIH-funded CRISP imaging study, the NIH-funded HALT-PKD clinical trial, and Industry-funded clinical trials of tolvaptan. He is the PI of a DOD funded program project investigating the role of cyclic AMP and protein kinase A signaling in PKD. His contributions to PKD research were recognized by the 2007 Lillian Jean Kaplan International Prize for Advancement in the Understanding of PKD and the 2019 John P. Peters Award of the American Society of Nephrology. He has served as Chair of the Division of Nephrology and Hypertension at the Mayo Clinic, Director and co-Director of the Mayo Translational PKD Center, Director of the NIH-funded Mayo Kidney Disease Research Training Grant, and on the Scientific Advisory Board of the PKD Foundation, and several editorial boards and NIH study sections and committees. He has organized several meetings on PKD, the 2014 Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference dedicated to PKD, the 2017 FASEB Science Research Conference on PKD, and served as Working Group Co-Chair for the development of the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD.